Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of C1K (Charis 1000) in Healthy Subjects
NCT05980065Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of C1K in triple-negative breast cancer (TNBC) and solid tumor (5 arms), sponsored by Seoul National University Hospital. Primary endpoints: Safety assessment by adverse event monitoring up to 23 days, Maximum Plasma Concentration at Day 15 and 1 more. Started Dec 2022; status: completed.
02
Drugs
C1K
03
Conditions
triple-negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on NCT05980065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980065.